1. Home
  2. TBPH vs PDX Comparison

TBPH vs PDX Comparison

Compare TBPH & PDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$16.08

Market Cap

824.9M

Sector

Health Care

ML Signal

HOLD

Logo PIMCO Dynamic Income Strategy Fund of Beneficial Interest

PDX

PIMCO Dynamic Income Strategy Fund of Beneficial Interest

HOLD

Current Price

$21.68

Market Cap

920.1M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
TBPH
PDX
Founded
2013
2019
Country
United States
NY
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
824.9M
920.1M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
TBPH
PDX
Price
$16.08
$21.68
Analyst Decision
Buy
Analyst Count
6
0
Target Price
$18.40
N/A
AVG Volume (30 Days)
289.3K
87.1K
Earning Date
05-04-2026
01-01-0001
Dividend Yield
N/A
4.95%
EPS Growth
279.13
N/A
EPS
N/A
N/A
Revenue
$15,386,000.00
N/A
Revenue This Year
$8.46
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.98
$18.47
52 Week High
$21.03
$25.25

Technical Indicators

Market Signals
Indicator
TBPH
PDX
Relative Strength Index (RSI) 40.51 58.17
Support Level $13.41 $21.50
Resistance Level $17.21 $22.14
Average True Range (ATR) 0.34 0.29
MACD -0.06 0.01
Stochastic Oscillator 4.84 65.35

Price Performance

Historical Comparison
TBPH
PDX

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.

About PDX PIMCO Dynamic Income Strategy Fund of Beneficial Interest

PIMCO Dynamic Income Strategy Fund is a non-diversified, limited-term, closed-end management investment company. It seeks current income as a primary objective and capital appreciation as a secondary objective. The fund makes investments using a dynamic asset allocation plan among multiple sectors in the public and private credit markets globally, including corporate debt, mortgage-related and other asset-backed instruments, government and sovereign debt, taxable municipal bonds, and other fixed, variable, and floating-rate income-producing securities of U.S. and foreign issuers, including emerging market issuers and real estate-related investments.

Share on Social Networks: